Hut 8 Corp vs Zoetis Inc — how do they compare? Hut 8 Corp trades at $83.77 (market cap $9.82B), while Zoetis Inc trades at $74.56 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 3.1× Hut 8 Corp's market cap, and Zoetis Inc pays a 2.9% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and Zoetis Inc for 70 Days on average.
| HUT | ZTS | |
|---|---|---|
Market Cap | $9.82B | $30.20B |
Volume | 10,272,678 | 6,175,327 |
Sector | Financials | Health |
52-Week High | $133.02 | $147.53 |
52-Week Low | $33.76 | $69.09 |
Typical Hold Time | 11 Days | 70 Days |
Enterprise Value | $17.25B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Hut 8 Corp. (HUT) trades at $81.20, down 9.07% amid a bearish technical signal. The company reported a net loss of $226.15 million in 2025 despite revenue of $235.12 million, with negative cash flow from operations. Recent news highlights a $1.07 billion credit facility and strong analyst buy ratings, with a consensus price target of $162.69 suggesting significant upside potential.
The outlook is mixed: robust analyst support and AI infrastructure growth opportunities contrast with persistent losses and high valuation ratios. Key risks include execution on profitability and sensitivity to sector sentiment. The stock's near-term direction hinges on earnings improvement and contract execution.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →